MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Deferoxamine mesylate

CAS No. : 138-14-7

MCE 站：Deferoxamine mesylate

产品活性：Deferoxamine mesylate是一种铁螯合剂，可将游离铁与稳定的复合物结合，防止其发生化学反应。

研究领域：Autophagy  |  Neuronal Signaling  |  Apoptosis

作用靶点：Autophagy  |  Amyloid-β  |  Mitophagy  |  Ferroptosis

In Vitro: Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals. Deferoxamine (5 μM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 μM and 100 μM deferoxamine. Deferoxamine (5 μM-100 μM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs. Deferoxamine (30, 60, 120?μM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs.

In Vivo: Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental. Ten ?L of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Diabetes Related Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Anti-COVID-19 Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer’s Disease Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  3-Methyladenine  |  Erastin  |  Ferrostatin-1  |  Cisplatin  |  Doxorubicin hydrochloride  |  Cycloheximide  |  RSL3  |  SB 203580  |  Acetylcysteine  |  SP600125  |  Dexamethasone  |  Metformin hydrochloride  |  Necrostatin-1  |  U0126-EtOH  |  Etoposide  |  AICAR  |  DAPT  |  Brefeldin A  |  Rosiglitazone  |  Resveratrol  |  SB 202190  |  Quercetin  |  Melatonin  |  Curcumin  |  Valproic acid  |  Sunitinib  |  Tanespimycin  |  Hemin  |  (-)-Epigallocatechin Gallate  |  TBHQ

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。